RCM
ALXN

Riverhead Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Riverhead Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$638K Buy
6,517
+800
+14% +$90.2K 0.02% 618
2019
Q2 		$749K Sell
5,717
-2,913
-34% -$375K 0.03% 582
2019
Q1 		$1.17M Buy
8,630
+2,075
+32% +$258K 0.05% 438
2018
Q4 		$638K Buy
6,555
+82
+1% +$9.69K 0.03% 572
2018
Q3 		$900K Buy
6,473
+100
+2% +$12.5K 0.03% 515
2018
Q2 		$791K Buy
6,373
+613
+11% +$71.6K 0.03% 519
2018
Q1 		$642K Sell
5,760
-132
-2% -$15.8K 0.03% 552
2017
Q4 		$705K Buy
5,892
+1,225
+26% +$149K 0.03% 535
2017
Q3 		$655K Sell
4,667
-700
-13% -$95.1K 0.03% 515
2017
Q2 		$653K Buy
5,367
+399
+8% +$46.4K 0.03% 500
2017
Q1 		$602K Buy
4,968
+801
+19% +$103K 0.03% 482
2016
Q4 		$510K Sell
4,167
-600
-13% -$73.4K 0.03% 493
2016
Q3 		$584K Sell
4,767
-89,261
-95% -$11.5M 0.04% 426
2016
Q2 		$872K Buy
94,028
+76,343
+432% +$10.8M 0.03% 465
2016
Q1 		$2.46M Sell
17,685
-8,752
-33% -$1.29M 0.03% 469
2015
Q4 		$5.04M Buy
26,437
+595
+2% +$104K 0.07% 327
2015
Q3 		$4.04M Sell
25,842
-1,449
-5% -$264K 0.06% 335
2015
Q2 		$4.93M Buy
27,291
+1,380
+5% +$238K 0.07% 323
2015
Q1 		$4.49M Buy
25,911
+713
+3% +$129K 0.07% 326
2014
Q4 		$4.66M Sell
25,198
-152
-0.6% -$28.2K 0.07% 309
2014
Q3 		$4.21M Buy
25,350
+2,717
+12% +$446K 0.07% 313
2014
Q2 		$3.54M Buy
22,633
+4,060
+22% +$641K 0.07% 332
2014
Q1 		$2.83M Buy
18,573
+772
+4% +$123K 0.06% 341
2013
Q4 		$2.37M Buy
17,801
+6,801
+62% +$816K 0.06% 320
2013
Q3 		$1.28M Hold
11,000
– – 0.04% 323
2013
Q2 		$1.01M Buy
+11,000
New +$1.06M 0.03% 339

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Riverhead Capital Management's ALXN Position: Q3 2019 in Review

Riverhead Capital Management increased its Alexion Pharmaceuticals (ALXN) stake by 14% in Q3 2019, buying an estimated $90.2K and bringing the position to 6,517 shares worth $638K. The position accounts for 0.02% of the portfolio, ranked #618.

Riverhead Capital Management first reported a position in ALXN in Q2 2013 and has held it in 26 quarters since. The position peaked at $5.04M in Q4 2015. 647 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

  • Riverhead Capital Management held 6,517 shares of Alexion Pharmaceuticals worth $638K as of Q3 2019.
  • Riverhead Capital Management bought 800 Alexion Pharmaceuticals shares in Q3 2019, an estimated $90.2K.
  • Alexion Pharmaceuticals made up 0.02% of Riverhead Capital Management's portfolio in Q3 2019, its #618 holding.
  • Riverhead Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 26 quarters since.
  • Riverhead Capital Management's Alexion Pharmaceuticals position peaked at $5.04M in Q4 2015.
  • 647 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.